One of the main benefits of azacitidine is its ability to improve the quality of life and extend survival in patients with myelodysplastic syndromes. Clinical studies have shown that azacitidine can reduce the need for blood transfusions, decrease the risk of progression to acute myeloid leukemia, and improve overall survival. Its relatively mild side effect profile compared to other chemotherapeutic agents makes it a viable option for elderly patients and those with comorbid conditions.
